Send Inquiry
Why Umbilical Cord Source?
Umbilical cord-derived MSCs offer distinct advantages over bone marrow or adipose sources. They demonstrate higher proliferation rates, faster self-renewal, and lower immunogenicity, making them well-suited for allogeneic applications -1. Notably, umbilical cord MSCs also produce the highest exosome yield among MSC sources, a critical factor for scalable manufacturing -16. Their molecular cargo is enriched with anti-inflammatory and pro-regenerative factors, including TGF-1, VEGF, HGF, and various regulatory RNAs (miRNAs, lncRNAs, circRNAs) that modulate target cell functions -18.
Mechanisms of Action
hUC-MSC-Exos exert therapeutic effects through multi-target, multi-pathway mechanisms rather than a single mode of action. In wound healing and skin regeneration, they promote fibroblast proliferation and migration, stimulate angiogenesis in endothelial cells, reduce inflammation, and enhance extracellular matrix formation -4. Mechanistically, studies have linked their activity to activation of the Wnt/-catenin signaling pathway, which helps maintain skin homeostasis and mitigate keratinocyte mitochondrial damage under inflammatory stress -3. Specific exosomal miRNAs (e.g., miR-136, miR-335-5p, miR-1246) have been identified as key effectors in these processes -18.
Therapeutic Potential
Preclinical and early clinical studies have explored hUC-MSC-Exos across a range of indications. In diabetic wound healing, exosome-loaded hydrogels significantly accelerated wound closure and promoted complete skin regeneration in animal models -12. For atopic dermatitis, topical application via thermosensitive hydrogel reduced inflammation and repaired the skin barrier -3. Clinical trials are underway for vitiligo, ARDS due to COVID-19, diabetic foot ulcers, and intrauterine adhesions -7-14. A first-in-human study of intra-articular administration for knee osteoarthritis has also been initiated, representing a step toward clinical-grade translation -11.
Send Inquiry
